化合物LDN-214117 T1944

Product Introduction
Bioactivity


英文名: LDN-214117

描述: LDN214117 是一种高效的 ALK2 选择性抑制剂(IC50:22nM)，也是一种 BMP6 抑制剂(IC50:100nM)，对ALK5抑制力弱100倍。

细胞实验: Cells are seeded at 25000 cells per well in 96-well plates and incubated for 2 h at 37℃ and 5% CO2. Compounds of LDN-214117 or DMSO are diluted in DMEM and added at ?nal compound concentrations of 1, 10, and 100 μM. Cells are incubated for 4 and 24 h, after which the media is discarded. Cells are lysed by adding 30 μL of passive lysis bu?er and shaken at RT for 15 min. Cell viability is determined by quantifying the ATP present in each well by adding 10 μL of Cell Titer Glo per well and measuring the light output by Spectramax L luminometer. Data is normalized to 100% viability for cells receiving only DMSO.(Only for Reference)

激酶实验: ALK2 kinase assay: Puri?ed recombinant ALK2 proteins, ATP, ATP[γ-32P], and dephosphorylated casein at ?nal concentrations of 2.5 nM, 6 μM, 0.05 μCi/μL , and 0.5 mg/mL, respectively, are aliquoted in kinase bu?er containing 0.2% BSA supplemented with 10 mM MnCl2 into 96-microwell plates, in combination with inhibitor compounds diluted at varying concentrations (0.01 nM to 100 μM). Positive control samples lacking inhibitor compounds, and negative controls lacking recombinant kinase, are also measured. The mixture is reacted at RT for 45 min, quenched with a ?nal concentration of 2% phosphoric acid. The reaction mixture is transferred to 96-well P81 phosphocellulose ?lter plates and bound for 5 min. The plates are washed 20 times with 150 μL of 1% phosphoric acid solution per well by vacuum manifold. Plates are dried at RT for 1 h, sealed, and assayed with Microscint 20 scintillation ?uid using a Spectramax L luminometer. Data is normalized to positive controls at 100% enzyme activity, with negative controls being subtracted as background.

体内活性: LDN-214117对BMP6比对BMP2或BMP4表现出相对的选择性抑制。在基于细胞的测定中,LDN-214117对BMP6表现出选择性抑制,IC50约为100 nM,作用于BMP6比作用于TGF-β1选择性高164倍。LDN-214117高度抑制的激酶为ALK2,IC50为24 nM,其次为TNIK,RIPK2和ABL1。LDN-214117选择性抑制ALK2和ALK1激酶活性,抑制作用高于ALK3激酶。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 42 mg/mL (100 mM)
DMSO : 42 mg/mL (100 mM)


关键字: ALK2 | BMP4 | BMP2 | Transforming growth factor beta receptors | LDN-214117 | BMP6 | TGF-β Receptor | diffuse intrinsic pontine glioma(DIPG) | oral | ALK3 | fibrodysplasia ossificans progressiva (FOP) | ALK5 | type I receptor kinases | ALK1 | LDN214117 | bone morphogenetic proteins (BMPs) | LDN 214117

相关产品: KRCA-0008 | OD36 | Brigatinib | ZX-29 | Crizotinib | OD36 hydrochloride | 6-Demethoxytangeretin | ALK2-IN-2 | MS4078 | IN-1130

相关库: Anti-Liver Cancer Compound Library | Membrane Protein-targeted Compound Library | Anti-Lung Cancer Compound Library | Cancer Cell Differentiation Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Obesity Compound Library | Tyrosine Kinase Inhibitor Library | TGF-beta/Smad Compound Library | Stem Cell Differentiation Compound Library

化合物LDN-214117 T1944信息由TargetMol中国为您提供，如您想了解更多关于化合物LDN-214117 T1944报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途